Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms YX-2-233 |
Target |
Action inhibitors |
Mechanism CDK4 inhibitors(Cyclin-dependent kinase 4 inhibitors), CDK6 inhibitors(Cyclin-dependent kinase 6 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC65H79Cl2N13O6 |
InChIKeyIGNFCLYXCYPVEB-NXURCQBISA-N |
CAS Registry- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Philadelphia positive acute lymphocytic leukaemia | Preclinical | United States | 30 Apr 2020 |